Green Thumb Industries Shares Slid Even Though It Turned A Profit

If you had paused on Green Thumb Industries back in early October 2025, waiting for federal reform or wellness trends to feel more certain, you skipped a trade that looked compelling on paper but played out very differently. Investors who held Green Thumb Industries over the past year are down 23.3%, including dividends. With that result in hand, which early assumptions about legalization, pricing pressure, or share buybacks would you now interrogate most closely?

Green Thumb Industries has already moved. See which of 7 high quality undervalued stocks still trade below our estimates.

The Two Stories Green Thumb Investors Were Choosing Between

At the start of this period, Green Thumb Industries shares cost CA$12.25, and you were effectively being asked which story about federal reform, pricing, and consumer demand you trusted more.

The bullish narrative pointed to a Fair Value of CA$22.09. This was the price implied if generous assumptions played out, built on accelerating EPS from ongoing share repurchases and the idea that federal legalization would open the door to institutional capital and a higher sector P/E.

The bearish view anchored on a Fair Value of CA$10.90. This more cautious implied price focused on regulatory uncertainty, oversupply-driven price compression, and the risk that expensive acquisitions of distressed assets could dilute future returns.

What The Results Changed For Green Thumb Industries

The rescheduling of medical cannabis to Schedule III gave Green Thumb Industries access to 280E tax relief, and Q2 2026 results showed revenue of US$306.7 million and a net margin of 1.6%. That shift from a slight loss in Q2 2025 to a small profit supported the optimistic case on tax and cash flow, yet ongoing sector pricing pressure kept the cautious story alive. Overall, the evidence cut both ways.

The key lesson is simple. When a thesis leans on regulation and tax, track the exact net margin and cash generation after the rule change, and compare those numbers with what management implied before you commit fresh capital to any similar policy-driven story.

What You Are Really Paying For In Green Thumb Industries Today

Green Thumb Industries now trades at CA$9.32, with the selected Narrative arguing that its Fair Value sits above that level based on current operations and balance sheet strength. The focus is less on broad consolidation and more on how cash, buybacks, and federal rescheduling interact.

The Narrative leans on THC beverages, regulated channels, and brand strength as the differentiators that could matter most. For that higher figure to make sense, a buyer today would need to assume Green Thumb Industries keeps expanding federally compliant THC beverages into mainstream outlets at scale.

"Growing placement of RYTHM Inc. beverages like Seniorita THC margaritas and 1777 by Seniorita in mainstream outlets such as Circle K, Target, Total Wine, and major arenas introduces a non dispensary path to scale for the portfolio, which can add a distinct revenue stream and mix shift that supports EBITDA margins."

That disagreement has a full argument behind it. → Uncover the higher Fair Value this Narrative argues for

Looking Past Green Thumb Industries

Green Thumb gives you exposure to regulated consumption and changing health habits. One step away, another business is tackling a different side of wellness.

Instead of beverages and dispensaries, this firm concentrates on medicines for weight and blood sugar. These treatments can change how patients manage chronic metabolic conditions.

Once a drug clears development, producing each additional dose can be relatively cheap. Most of the effort sits upfront, so approvals may support strong profitability.

For a portfolio, that creates a very different engine from a cannabis operator like Green Thumb Industries. How much of your health exposure leans on lifestyle trends versus prescription power?

One Narrative has already put a figure on it. → Uncover the company trading 21% below one Narrative's Fair Value

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com